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Abstract: There is increasing evidence for the involvement of the skeleton in the regulation of
atherosclerotic vascular disease. Osteocalcin, an osteoblast derived protein, exists in two forms,
carboxylated and undercarboxylated osteocalcin. Undercarboxylated osteocalcin has been linked
to the regulation of metabolic functions, including glucose and lipid metabolism. Features of
atherosclerosis have been associated with circulating osteocalcin; however, this association is
often conflicting and unclear. Therefore, the aim of this review is to examine the evidence for a
role of osteocalcin in atherosclerosis development and progression, and in particular endothelial
dysfunction and vascular calcification. The current literature suggests that undercarboxylated
osteocalcin stimulates the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway
to upregulate nitric oxide and nuclear factor kappa β (NF-
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osteocalcin stimulates the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway 
to upregulate ni ric oxide and nuclear factor kappa β ( кβ) in vascular cells, possibly protecting 
endothelial function and preventing atherogenesis. However, this effect may be mediated by 
metabolic factors, such as improvements in insulin signaling, rather than through a direct effect on 
the vasculature. Total osteocalcin is frequently associated with vascular calcification, an association 
that may occur as a result of vascular cells eliciting an osteogenic phenotype. Whether osteocalcin 
acts as a mediator or a marker of vascular calcification is currently unclear. As such, further studies 
that examine each form of osteocalcin are required to elucidate if it is a mediator of atherogenesis, 
and whether it functions independently of metabolic factors. 
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
ascular cells, possibly protecting
endothelial functio and pr ve ting atherogenesis. However, ef ect may be mediated by
metabolic factors, such as improvements in insulin signali , rat er than through a direct effect on
the vasculature. Total osteocalcin is frequently associated with vascular calcification, an association
that may occur as a result of vascular cells eliciting an osteogenic phenotype. Whether osteocalcin
acts as a mediator or a marker of vascular calcification is currently unclear. As such, further studies
that examine each form of osteocalcin are required to elucidate if it is a mediator of atherogenesis,
and whether it functions independently of metabolic factors.
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1. Introduction
Cardiovascular disease describes a group of disorders that affect the myocardium and vasculature
and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or atherosclerosis, is the
most common cause of cardiovascular related deaths [3,4]. The development of atherosclerosis
is characterized by distinct phases, including endothelial dysfunction, intimal thickening, plaque
development, and, in the chronic stage, vascular calcification [5]. Numerous risk factors are responsible
for the development of atherosclerosis, including diabetes, ageing, smoking, low physical activi y
levels, oor diet, and fa ily history [6,7]. Diabetes, which is haracterized by hyperglycemia and
insulin resistance, is a leading risk factor for the development of atherosclerosis [2]. Abnormal insulin
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signaling, advanced glycation end-products, and oxidative stress caused by hyperglycemia and insulin
resistance may promote the pathological interaction between diabetes and atherosclerosis [8–11].
Recently, the skeleton has been established as an endocrine organ participating in several
metabolic processes, including the maintenance of circulating blood glucose and lipid levels.
This bone/endocrine “cross talk” is thought to be regulated, at least in part, via osteocalcin, a vitamin
K-dependent, osteoblast-derived protein [12–15]. Total osteocalcin includes both undercarboxylated
osteocalcin (ucOC) and carboxylated osteocalcin (cOC). UcOC is characterized by the presence
of 0–2 gamma-carboxyl groups on glutamic acid residues and is predominantly released into
circulation [16]. The presence of 3 gamma-carboxyglutamic acid residues produces carboxylated
osteocalcin (cOC), which has a high affinity for hydroxyapatite and is located predominantly in
the bone matrix [17,18]. Vitamin K is essential for carboxylation and, as such, circulating levels of
osteocalcin are used as a marker of vitamin K status [19]. Generally, ucOC makes up between 40 and
60% of total circulating osteocalcin [20–22]. The role of osteocalcin in the regulation of endocrine
outcomes has been discussed in a number of recent review studies [23–27] and is thus not examined in
this review.
The discovery of osteocalcin as a regulator of metabolic processes has led to investigations
considering associations with cardiovascular disease. Several cross-sectional studies have
demonstrated that circulating levels of total osteocalcin and ucOC are associated with both metabolic
and cardiovascular disorders [28–32]. However, it is unclear whether osteocalcin has a direct role in
the vasculature, independent of metabolic outcomes, or whether the association is mediated indirectly,
via the metabolic effects of ucOC. Furthermore, advanced atherosclerotic plaques are characterized
by the development of calcification, a process that involves a shift in vascular cells to an osteogenic
phenotype [33]. Whether total osteocalcin, or one of the forms of osteocalcin, is a mediator or a
marker of this process, is of interest. Osteocalcin has the potential to be a target in future therapeutic
interventions for metabolic diseases such as diabetes and obesity [34]. Therefore, elucidating whether
total osteocalcin and each of its forms have a biological function in the vasculature, independent from
endocrine or metabolic outcomes, is of importance.
2. Atherosclerosis
Atherosclerosis typically presents in the coronary, cerebral, and peripheral arteries. The clinical
manifestations are myocardial infarction, stroke, and peripheral arterial disease [35]. Each layer of
the blood vessel contributes to the pathogenesis of atherosclerosis in a distinct way. For instance,
the tunica intima, which is comprised primarily of a layer of endothelial cells, forms a semi-permeable
barrier between the blood and the blood vessel wall [36]. Endothelial cell dysfunction is the initiating
factor in atherogenesis and involves a reduction in the bioavailability of nitric oxide (NO), a major
vasodilator and anti-atherogenic molecule. The reduction in NO results in an inflammatory response
that is characterized by the migration of smooth muscle cells from the tunica media. The adherence of
circulating molecules such as low-density lipoprotein (LDL) and cells, including leukocytes, contributes
to the formation of a fatty streak [37]. Subsequently, a lipid rich plaque develops and collagen content
increases. Finally, the advanced stages of atherosclerosis development are characterized by calcification
and fibrosis [38]. Evidently, the phenotype of an atherosclerotic plaque alters dramatically over the
life cycle of the disease. As such, it is of importance to distinguish between the stages when reporting
atherosclerotic outcomes [39]. This review will focus on two distinct features of atherosclerosis, namely,
the development of endothelial dysfunction and vascular calcification.
Endothelial dysfunction (vascular dysfunction) occurs in the initial stages of atherogenesis and
is present throughout the life cycle of the disease. It is a predictor of future adverse cardiovascular
events [40]. Normal endothelial function is regulated by a balance between anti-atherogenic (NO,
endothelial derived hyperpolarizing factor, and prostacyclin) and pro-atherogenic (endothelin-1,
thromboxane A2, and angiotensin II) factors [41,42]. The presence of a diseased state upsets the balance,
suppressing atheroprotective factors and promoting atherogenic factors. This imbalance results in
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several pathological effects, principally the inability of the endothelium to regulate vasomotor tone
(vasodilation and vasoconstriction) [36,43,44]. Abnormal vasomotor tone results in damage to the
endothelial cells lining the vascular wall and is associated with an inflammatory and coagulatory
response [43].
Advanced atherosclerosis, characterized by vascular calcification, involves the accumulation of
scattered calcium-like deposits [38,45]. The presence of calcification reduces blood vessel compliance,
causes stiffening of the vasculature, and is a predictor of future adverse health outcomes [46,47].
The development process of vascular calcification is similar to the process of bone formation in the
skeleton [48]. This process involves the accumulation of hydroxyapatite, the differentiation of smooth
muscle cells into osteoblast-like cells, the downregulation of calcification inhibitors, and the presence
of osteogenic proteins, such as Runx-2 and osteocalcin [49–51].
3. Association between Osteocalcin and Atherosclerosis Outcomes
3.1. Measurement of Osteocalcin in Humans
To date, it is not clear whether osteocalcin is biologically active during atherosclerosis development
in humans [16,27]. A recent meta-analysis included 46 studies examining the association between
osteocalcin and atherosclerosis outcomes. No clear relationship was reported between osteocalcin
and markers of atherosclerosis and calcification [52]. The presence of atherosclerosis was examined
via several methods, including aortic calcification score (ACS), coronary artery calcification score,
pulse wave velocity (PWV), and carotid intima-media thickness (C-IMT). Conflicting results were
reported across all the outcomes. For example, in the studies reporting the association between
osteocalcin and C-IMT, four reported that higher osteocalcin levels were associated with a higher
C-IMT, four reported that higher osteocalcin levels were associated with a lower C-IMT, and three
reported no correlation. Interestingly, all studies that examined osteocalcin-positive mononuclear cells
or completed histological staining for osteocalcin reported that higher osteocalcin levels were associated
with increased markers of atherosclerosis and calcification [52]. This suggests that osteocalcin may be
present in atherosclerosis, although, whether it has a regulatory function is not clear.
The conflicting outcomes presented in the meta-analysis may be due to a number of limitations.
First, total osteocalcin was reported in 43 of the studies, whereas some also included ucOC and
cOC, reported in 7 studies and 1 study, respectively. This is a major limitation as each form has
a distinct function [53,54]. Furthermore, different techniques were used to analyze osteocalcin.
For example, total osteocalcin has been measured with enzyme-linked immunosorbent assay (ELISA)
and radioimmunoassay (RIA), as well as flow cytometry and immunostaining, which may explain the
different findings.
Taken together, the meta-analysis did not provide a clear association between osteocalcin and
atherosclerosis. Consequently, the remainder of this review will focus on experimental studies that
report the effect or expression of osteocalcin, specifically examining if each form of osteocalcin has
distinct functions.
3.2. In Vivo Osteocalcin Treatment and Cardiovascular Function in Animal Models
The biological effects of osteocalcin are not fully known. A small number of studies have examined
the effect of total osteocalcin administration in vivo on the cardiovascular system in animal models
of disease. Tail cuff blood pressure (BP) was measured in apolipoprotein E-deficient (ApoE−/−)
mice, and the animals received daily injections of total osteocalcin (30 ng/g) for 12 weeks [55].
Total osteocalcin treatment had a protective effect on high-fat-diet-induced hypertension by reducing
mean and diastolic BP by ~5 and 7 mmHg, respectively. Similar trends occurred for systolic BP,
which was decreased by ~3 mmHg. Although an improvement in blood pressure occurred, there was
also a concomitant improvement in body weight, fasting blood glucose levels, glucose tolerance,
circulating lipids, and markers of inflammation in animals receiving osteocalcin treatment [55]. As such,
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it is not clear whether the observed improvements were due to a direct effect of osteocalcin on the
cardiovascular system, or indirectly via the improvement in the animals’ metabolic profile.
In another study, the administration of total osteocalcin repaired the alteration to PWV,
concurrently with improvements in fasting blood glucose and circulating lipids [56]. Specifically,
PWV, which is a measure of arterial stiffness, was increased (by 6%) in a rat model fed a high-fat
diet and induced with diabetes via streptozotocin injection. Following 12 weeks of a high-fat diet,
daily intraperitoneal injections of total osteocalcin (30 ng/g) reversed the alteration in PWV, albeit by
a small magnitude. Blood pressure, heart rate, and mean arterial pressure were not altered by the
high-fat diet or the osteocalcin injections [56]. This study suggests that a daily injection of total
osteocalcin can repair abnormal cardiovascular function (Table 1). However, whether the protective
effect occurred directly, or as a result of improved metabolic outcomes, is still not clear.
Table 1. Summary of studies examining the effects of in vivo osteocalcin treatment on vascular function
outcomes in animals.
First Author,
Year [Ref.] Experimental Overview
Measurement of
Vascular Function Results
Dou, 2014 [55]
ApoE-/- mice received ND or HFD and
treatment daily for 12 weeks with
vehicle or total osteocalcin (30 ng/g)
BP, heart rate, and
isometric myography
In vivo: mean and diastolic BP normalized by
osteocalcin treatment in HFD group, no change
in systolic BP or heart rate.
Ex vivo: 20% improvement in relaxation in
osteocalcin-treated mice on HFD
Huang, 2017 [56]
Sprague Dawley rats induced with
diabetes via STZ injection and received
ND or HFD, daily treatment of vehicle
or total osteocalcin (30 ng/g) for
12 weeks
BP, PWV, heart rate,
pulse pressure, and
mean arterial pressure
PWV normalized in osteocalcin-treated rats
with diabetes compared to diabetic rats treated
with vehicle, no change in BP, heart rate, mean
arterial pressure, and pulse pressure
Kondo, 2016 [57]
Wild type C57BL/6 mice received HFD
and treated 5 times a week for 10 weeks
with vehicle or ucOC (30 ng/g)
Nitric oxide production
Increased nitric oxide concentration in
ucOC-treated mice compared to
vehicle-treated mice
Zhou, 2013 [58]
C57BL/6J mice received ND or HFD for
8 weeks with daily injections of vehicle
or ucOC (30 ng/g)
Autophagy and ER stress Autophagy and ER stress attenuated in micereceiving ucOC
ApoE = apolipoprotein E, HFD = high -fat diet, ND = normal chow diet, STZ = streptozotocin,
ucOC = undercarboxylated osteocalcin, BP = blood pressure, PWV = pulse wave velocity, ER = endoplasmic reticulum.
3.3. In Vivo Osteocalcin Treatment and Markers of Atherosclerosis Risk in Animal Models
Isometric/isotonic myography is an ex vivo technique used to examine endothelial function
directly, independent of factors such as sheer stress and circulation hormones. This technique was used
to examine the function of the thoracic aorta in ApoE-/- mice following 12 weeks on a high-fat diet,
receiving simultaneous daily injections of total osteocalcin (30 ng/g) or vehicle [55]. Vehicle-treated
mice had a reduction in endothelial function by 20%, a pathological effect that was attenuated in the
mice receiving osteocalcin treatment. An examination of the mechanisms revealed that co-incubation
with NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase, blocked the
relaxation of all groups. However, co-incubation with sodium nitroprusside (SNP), a nitric oxide donor
that is endothelium-independent, resulted in a similar relaxation between total osteocalcin-treated
and non-treated tissue. The relaxation of all vessels to SNP demonstrates that the high-fat diet or total
osteocalcin does not affect the ability of vascular smooth muscle cells to respond to nitric oxide [55].
Thus, total osteocalcin appears to have a protective effect on endothelial function that may assist in the
prevention of atherosclerosis.
Whether one or both forms of osteocalcin were responsible for this effect is unclear. As a result,
each form of osteocalcin was administered to female wild type C57BL/6 mice, to determine the effect on
nitric oxide availability. Treatment with ucOC (30 ng/g), but not an equivalent dose of cOC, increased
serum nitric oxide, providing further evidence that it is the bioactive form of the protein, at least in
mice [57]. Subsequently, ucOC (30 ng/g) was administered via intraperitoneal injection 5 times per
week for 10 weeks into mice fed an atherogenic (F2HFD1) diet. The diet did not induce the development
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of atherosclerotic plaques, but it did increase total cholesterol, LDL, and LDL/high density lipo-protein
(HDL) ratio, all of which are associated with an increased risk of atherosclerosis. UcOC administration
significantly lowered all the lipid markers and produced a 1.7-fold increase in serum nitric oxide
bioavailability compared to saline-treated mice [57]. The improvement in lipid markers and serum
nitric oxide availability would likely assist in the prevention of atherosclerosis development.
Furthermore, eight weeks of daily ucOC (30 ng/g) treatment following a high-fat diet produced an
improvement in insulin signaling and a reduction in autophagy and ER stress in the aorta of C57BL/6J
mice [58]. Several markers of autophagy (Atg7, p62, and light chain 3 II (LC3-II)) and ER stress (protein
kinase-like endoplasmic reticulum kinase (PERK) and eukaryotic initiation factor 2α (eIF2α)) were
increased in the high-fat diet-fed mice. However, the administration of ucOC following the high-fat
diet attenuated the pathologic autophagy and ER stress marker response. Moreover, insulin resistance
was detected in the high-fat-diet-fed mice, as measured by a reduction in the phosphorylation of insulin
receptor β (IRβ) subunit tyrosine 1162/1163 and protein kinase B (Akt) Ser-473. An improvement
in insulin signaling in ucOC-treated mice, as seen by an increase in the IRβ subunit and Akt Ser-473
phosphorylation, demonstrates that ucOC rescues high-fat-diet-induced insulin resistance in mouse
aorta [58].
In summary, in vivo ucOC treatment protects vascular function and pathological disease markers
that often contribute to or are involved in the development of atherosclerosis (Table 1). However,
the protective effects of ucOC on the vasculature are often associated with improved metabolic
outcomes, such as improvements in insulin signaling or lipid markers. As such, in vitro studies
are needed to confirm (1) whether osteocalcin and its forms are acting directly on vascular tissue,
and (2) that ucOC is the active form of osteocalcin mediating these effects.
4. Osteocalcin and Endothelial Function
4.1. In Vitro Osteocalcin Treatment in Human Cells
The endothelium has an important role in maintaining vascular homeostasis because it mediates
the release of a number of regulatory factors [41]. Molecular signaling mechanisms that regulate
vascular function have been examined in several studies to determine if there is a direct link between
osteocalcin and atherosclerosis development (Table 2).
Human umbilical vein endothelial cells (HUVECs) cultured with total osteocalcin (10–150 ng/mL)
displayed a dose-dependent upregulation of Akt and endothelial nitric oxide synthase (eNOS)
phosphorylation—up to 100 ng/mL of total osteocalcin [55]. Akt is a common protein kinase involved
in numerous cellular signaling pathways, including the phosphorylation of eNOS via serine1177;
eNOS synthesizes NO [59]. When treated with 100 ng/mL of total osteocalcin, Akt and eNOS
phosphorylation increased, peaking at 1 h and 2 h following treatment, respectively [55]. Of note,
the properties of HUVECs are not ubiquitous to all endothelial cells, therefore the findings cannot
be directly associated with adult endothelial function [60]. Despite this, similar results have been
reported in human aortic endothelial cells (HAECs). HAECs incubated with ucOC or cOC for 30 min
resulted in an increase in eNOS phosphorylation in cells treated with 25 and 100 ng/mL of ucOC by
~1-fold and ~2.5-fold, respectively. However, equivalent doses of cOC had no effect [57]. Similarly,
eNOS phosphorylation and nitric oxide secretion were increased in a dose-dependent manner between
0.3–30 ng/mL of ucOC treatment in HAECs [61]. Mechanistic investigation demonstrated that the
phosphorylation of Akt/eNOS by ucOC was inhibited by the addition of wortmannin, an inhibitor of
phosphoinositide 3-kinase (PI3K), which is the protein kinase responsible for phosphorylating Akt [61].
Taken together, these results indicate that ucOC may upregulate nitric oxide synthesis via the
activation of the PI3K/Akt/eNOS signaling pathway in human endothelial cells, which may have
a protective effect against endothelial dysfunction. Again, these findings support previous research
suggesting that ucOC is the biologically active form of the protein. UcOC may have a protective
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function in the vasculature, independent from its influence on metabolic outcomes, however further
studies are required to confirm this (Figure 1).
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activi y levels, poor d et, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
= uclear factor kappa β, mTOR = mammalian
target of rapamycin, ER = endoplasmic reticulum.
Several pathological mechani ms promote th dev lopm nt of endothelial dysfunction and
atherosclerosis, including elevated apoptosis and endoplasmic reticulum (ER) stress. UcOC (30 ng/mL)
treatment prior to the administration of linoleic acid, which acts as a free fatty acid, inhibited the
induction of apoptosis in HAECs via the PI3K/Akt pathway [61]. Additionally, HUVECs exhibited
ER stress a d insulin re i ta ce when incubat d with tunicamycin; however, co-incubation with
ucOC (5 ng/mL) for 4 h reduced th ER stress and increased t e phosphorylation of insulin re eptor
substrate 1 (IRS-1), a molecule involved in insulin ig al transduction [62]. The co-incubatio of
wortmannin and Akti— /2 (an Akt inhibit r) blocked th insulin sensitizing effect of ucOC. However,
U0126 ( mitogen-activated protein inase (MAPK) inhibitor) did not block the effect of ucOC.
Additionally, nuclear factor kappa β (NF-
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
, a key cellular signaling molecule, which was suppressed
by tunicamycin, exhibited a normalization when co-incubated with ucOC. Further ore, the inhibition
of NF-
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
s gnaling and the silencing of the NF-
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1. Introduction 
Cardiovascular isease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
th ros lerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterize  by distinct phases cluding endothelial dysfunction, intimal 
thickening, plaque de elopment, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the evelopment of atherosclerosis including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk fact r for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
p65 gene confirmed that NF-
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1. Introduction 
Cardiovascular disea e scribes  group of disor ers that affect the myocardium and 
vascul ture and is the leading cause of death wo ldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular relat d deaths [3,4]. The development of 
atherosclerosis is character ze  by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque dev l pment, and, in the hr ic stage, vasc la  calcification [5]. Numerous risk 
factors are r spons ble for the development of ath rosclerosi , including diabetes, ageing, smoking, 
l w physical activit  levels, poor diet, and fam ly history [6,7]. Dia etes, which is characterized by 
hyperglycemia and insulin resistance, is a l ading risk f cto  for the development of atherosclerosis 
[2]. Abnormal insulin sig aling, advance glyc on end-products, and oxidative stress caused by 
was volved in
the regulation of ER s ress and insuli sign ling by ucOC [62]. The result from this study sugg st that
ucOC suppresses ER stress via the PI3K/Akt/NF-
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the develop ent of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
s gnaling pathway an that improved insulin
e si vity i itiates this response.
Collectively, it appe rs that ucOC may elicit an atheroprotective ffect in human endothelial cells.
The protective effects of ucOC often occurred through improved insulin signaling or in the presence of
high lipid content. However, ucOC also produced a protective effect in endothelial cells without the
presence of any etabolic mediators, suggesting that osteocalcin may have a direct bioactive influence
in human endothelial ce ls.
Nutrients 2018, 10, 1426 7 of 15
Table 2. Summary of cell culture studies examining the effects of in vitro osteocalcin treatment in
human and animal vascular cells.
First Author,
Year [Ref.] Experimental Overview Outcomes Results
Dou, 2014 [55]
HUVECs incubated with total osteocalcin
(10–150 ng/mL) for 15 min–2 h.
Descending aorta of ApoE-/- mice,
previously treated with osteocalcin,
incubated with LY294002 (10 µmol/L)
and Akt inhibitor V (5 µmol/L)
eNOS, Akt, and PI3K
phosphorylation
and expression
Max phosphorylation of eNOS and Akt with
100 ng/mL of osteocalcin. Max
phosphorylation of eNOS and Akt occurred
after 1 h and 2 h, respectively.
In aorta, PI3K, Akt, and eNOS phosphorylation
and expression increased, inhibited with
LY294002 and Akt inhibitor V
Kondo, 2016 [57]
HAECs incubated with ucOC (5, 25,
and 100 ng/mL) and cOC (25 and
100 ng/mL) for 30 min
eNOS phosphorylation
Incubation of ucOC increased eNOS
phosphorylation in a dose-dependent manner,
cOC had no effect
Jung, 2013 [61]
HAECs incubated with ucOC (0.3–30
ng/mL), linoleic acid (100 µmol/L for 16 h),
and wortmannin (100 nmol/L for 15 min)
Nitric oxide concentration,
eNOS and Akt
phosphorylation and
apoptosis
UcOC increased eNOS and Akt
phosphorylation and nitric oxide concentration,
which was inhibited by wortmannin.
UcOC attenuated linoleic acid-induced
apoptosis
Guo, 2017 [62]
HUVECs incubated with ucOC (5 ng/mL
for 4 h), tunicamycin (5 µg/mL for 4 h),
insulin (10 nM for 10 min), wortmannin,
and Akti-1/2 (10 µM for 4 h)
Insulin resistance, ER stress
UcOC blocked ER stress and insulin resistance,
which was inhibited by wortmannin
and Akti-1/2
Zhou, 2013 [58]
Mouse VECs and VSMCs incubated with
tunicamycin (5 µg/mL for 4 h),
ucOC (5 ng/mL for 0, 2, 4, and 8 h),
Akti-1/2 (10 µM for 4 h) and rapamycin
(10 nM for 4 h)
Autophagy and ER stress
UcOC attenuated autophagy and ER stress in
mouse VECs and VSMCs, which was inhibited
by Akti-1/2 and rapamycin
HUVECs = human umbilical vein endothelial cells, ApoE = apolipoprotein E, HAECs = human aortic endothelial
cells, ucOC = undercarboxylated osteocalcin, VECs = vascular endothelial cells, VSMCs = vascular smooth
muscle cells, eNOS = endothelial nitric oxide synthase, Akt = protein kinase B, PI3K = phosphoinositide 3-kinase,
ER = endoplasmic reticulum.
4.2. In Vitro Osteocalcin Treatment and Markers of Atherosclerosis Risk in Animal Cells
Animal studies have also been used to examine the effect of osteocalcin in vascular tissue and cells.
Experiments using cultured aortic strips obtained from ApoE-/- mice revealed that total osteocalcin
treatment increased the phosphorylation and expression of PI3K, Akt, and eNOS. Furthermore,
the phosphorylation of Akt and eNOS was blocked by the co-incubation of LY294002 and Akt inhibitor
V, which inhibit the signaling of PI3K and Akt, respectively [55]. UcOC (5 ng/mL) incubations in
mouse vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs) protected against
tunicamycin-induced autophagy and ER stress. The protective effect was mediated through the
Akt/mammalian target of rapamycin (mTOR) signaling pathway as a result of NF-
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1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
acti tion [58].
Similar results in cells from other orga s revealed that these eff cts may be systemic. For example,
ER stress and insulin resistance were both alleviated in L6 muscle cells when treated with 5 ng/mL of
ucOC for 4 h [63].
Overall, total osteocalcin and ucOC appear to protect against the development of atherosclerosis
through the activation of several signaling pathways (Table 2). NO is likely increased via the activation
of the PI3K/Akt/eNOS signaling pathway, which would result in an improvement in endothelial
function. However, increased eNOS expression can also enhance endothelial dysfunction by increasing
eNOS uncoupling and oxidative stress [64,65].
Further studies are needed to determine if the upregulation of eNOS prevents or enhances
endothelial dysfunction. Additionally, pathological abnormalities such as increased endothelial cell
apoptosis and ER stress, which contribute to the development of atherosclerosis, are abrogated by
ucOC treatment, likely acting through PI3K/Akt/NF-
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Abstract: There is increasing evid nc  for the involvem nt of the skeleton i  the regulation of 
atherosclerotic vascular disease. Osteocalcin, an osteoblast d rived protein, exists in two forms, 
carboxylated and undercarboxylated osteocalcin. Undercarboxylated osteocalcin has b en linked to 
the regulation of metabolic functions, including glucose and lipid metabolism. Feat res of 
atherosclerosis have been associated with circulating osteocalcin; however, this association is often 
conflicting and unclear. Therefore, the aim of this revi w is o exa ine the evidence for a role of 
osteocalcin in atherosclerosis development and progression, and in particular endothelial 
dysfunction and vascular calcificatio . The curren  litera ure suggests that un ercarboxylated 
osteocalcin stimulates the phosphoinos tide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway 
to upregulate nitric oxide and nuclear factor kappa β ( кβ) in vascular cells, possibly protecting 
endothelial function and preventing atherogenesis. However, this effect may be mediated by 
metabolic factors, such as improvements in insulin signaling, rather than through a direct effect on 
the vasculature. Total osteocalcin is frequently associated with vascular calcification, an association 
that may occur as a result of vascular cells eliciting an osteogenic phenotype. Whether osteocalcin 
acts as a mediator or a marker of vascular calcification is currently unclear. As such, further studies 
that examine each form of osteocalcin are required to elucidate if it is a mediator of atherogenesis, 
and whether it functions independently of metabolic factors. 
Keywords: undercarboxylated osteocalcin; carboxylated osteocalcin; endothelial dysfunction; 
vascular calcification; atherosclerosis; humans; animal models 
 
1. Introduction 
Cardiovascular disease describes a group of disorders that affect the myocardium and 
vasculature and is the leading cause of death worldwide [1,2]. Ischemic heart disease, or 
atherosclerosis, is the most common cause of cardiovascular related deaths [3,4]. The development of 
atherosclerosis is characterized by distinct phases, including endothelial dysfunction, intimal 
thickening, plaque development, and, in the chronic stage, vascular calcification [5]. Numerous risk 
factors are responsible for the development of atherosclerosis, including diabetes, ageing, smoking, 
low physical activity levels, poor diet, and family history [6,7]. Diabetes, which is characterized by 
hyperglycemia and insulin resistance, is a leading risk factor for the development of atherosclerosis 
[2]. Abnormal insulin signaling, advanced glycation end-products, and oxidative stress caused by 
/mTOR signaling. Whether these effects
occur exclusively through metabolic signaling pathways, or if ucOC has a direct biological effect in the
vasculature requires further investigatio .
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5. Osteocalcin and Vascular Calcification
5.1. Osteocalcin and Calcified Human Vascular Tissue
Several osteogenic factors, including the osteoblastic “master regulator” transcription factor
Runx2, have been shown to be expressed by smooth muscle cells located at the site of vascular calcified
plaques [66]. The expression of such factors may play a role in the osteogenic potential of these smooth
muscle cells. In addition, osteocalcin, which has been used clinically as a marker of bone formation,
has also been found at these sites [67]. It has thus been posited that osteocalcin may play a role in
the calcification of plaques, although whether this is true, or whether the association is coincidental,
requires further investigation.
Advanced atherosclerotic plaques are characterized by arterial stiffening, resulting in a reduction
in vessel compliance; this occurs as a consequence of vascular calcification [68]. Vascular calcification
increases the risk of adverse cardiovascular events, including aortic stenosis, reduced vasomotor tone,
and plaque instability [46]. Since the early 1980s, osteocalcin has been detected to a larger degree in
calcified plaques and aortic valves than in non-calcified and healthy vessels [69,70]. In fact, in vessels
obtained from men and women during autopsy, the concentration of total osteocalcin in calcified
vascular plaques was considerably higher (50.9 ng/mL) than the concentration present in fatty streaks
and fibrous plaques (1.1 ng/mL) and normal aortic tissue (0.33 ng/mL) [69]. Furthermore, a study
a decade later reported that the level of osteocalcin mRNA was increased between 8- and 14-fold in
calcified plaques and aorta compared to healthy aorta [71]. These findings predate the hypothesis
that osteocalcin may have a role in vascular function, yet demonstrate that the concentration of total
osteocalcin is positively correlated to the stage of atherosclerotic plaque progression. It is possible that
the increase in total osteocalcin occurs as a result of atherosclerotic plaques developing an osteogenic
phenotype [33], yet this requires further validation.
Vascular smooth muscle cells (VSMCs) are responsible for the development of atherosclerotic
calcification by differentiating into osteoblast-like cells [50]. Cultured VSMCs in the initial stages of
atherosclerosis formation undergo a downregulation of proteins that inhibit mineralization, leading to
a shift in the VSMCs to an osteo/chondrocytic phenotype. This change is characterized by an increase
in transcription factors regulating the expression of osteogenic proteins, including total osteocalcin [67].
Furthermore, total osteocalcin was shown to be minimally expressed in human aortic VSMCs cultured
to mimic the early stages of atherosclerosis [72]. In situ hybridization analysis demonstrated that
osteocalcin expression was significantly increased in lipid-rich, calcified VSMCs obtained from the
media and intima of explanted human aorta, compared to VSMCs without plaque development [73].
Modification of lipid content by treating VSMCs for 28 days with acylated low-density lipoprotein
did not alter osteocalcin expression, despite a 3-fold increase in calcification. Interestingly, incubation
of lipoprotein-deficient serum for 28 days in VSMCs was associated with an inhibition of calcium
formation, but an upregulation of osteocalcin expression [73]. This study demonstrates that VSMCs
developing an osteogenic phenotype modify the expression of total osteocalcin and are influenced by
the presence of lipids.
Overall, osteocalcin expression is increased in calcified lesions throughout the intimal and medial
layers of the vascular wall (Table 3). Whilst the increase in osteocalcin is often associated with the
development of an osteogenic phenotype, it is also associated with lipids. Of note, no studies have
differentiated between the forms of osteocalcin when discussing vascular calcification. Consequently,
an examination of ucOC and cOC and an investigation into the mechanisms that are associated with
the increase in osteocalcin in calcified tissue are required.
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Table 3. Summary of studies examining the interaction between osteocalcin and calcification in human
and animal tissue and cells.
First Author,
Year [Ref.] Experimental Overview Outcomes Results
Levy, 1983 [69] Human aortic and valve tissue Osteocalcin and Gla levels Osteocalcin and Gla levels higher in calcifiedtissue than in non-calcified tissue
Levy, 1980 [70] Human aortic and valve tissue Gla levels Higher Gla levels in calcified aorta andvalves than non-calcified tissue
Fleet, 1994 [71] Human aortic tissue Osteocalcin mRNA levels
Osteocalcin mRNA increased in calcified
aorta and plaque compared to non-calcified
aorta
Tyson, 2003 [67] Human aortic and carotid tissue Osteocalcin expression Calcified vessels had an increase in theexpression of osteocalcin
Severson, 1995 [72] Cultured human aortic VSMCs Immunostaining for osteocalcin Minimal immunostaining of human VSMCs
Proudfoot, 2002
[73]
Cultured human aortic VSMCs with
lipid content modification Osteocalcin expression
Osteocalcin expression increased in calcified
cells compared to non-calcified cells, which
was altered with the modification of lipid
content
Murshed, 2004 [74] MGP
-/- mice inter-crossed with
pSM22α-Osteocalcin
Mineralization of aorta Osteocalcin gain of function model did notinhibit the mineralization of mouse aorta
Pal, 2010 [75] OPG +/+ and OPG-/- mice
Calcification and mononuclear cells
expressing osteocalcin
Increased calcification in OPG-/- mice, which
was associated with an increased percentage
of osteocalcin positive mononuclear cells
Morony, 2008 [76] Ldlr
-/- mice fed HFD for 5 months and
treated with OPG
Calcification, osteocalcin mRNA
and circulating levels
Osteocalcin mRNA levels were unchanged,
circulating osteocalcin increased over the
5 months, which was associated
with calcification
Akiyoshi, 2016 [77] Thoracic aorta of C57BL/6 micecultured to induced calcification Osteocalcin expression
Osteocalcin expression increased in calcified
thoracic aortas
Idelevich, 2011 [78]
Cultured MOVAS cells induced with
calcification and overexpressed with
osteocalcin. Sprague Dawley rats
induced with calcification
Mineralization, osteocalcin mRNA,
metabolic signaling pathways
In vitro: overexpression of osteocalcin in
MOVAS cells associated with mineralization
and upregulation of insulin signaling
In vitro: osteocalcin mRNA is increased in
calcified vasculature and associated with
activation of metabolic signaling pathways
VSMCs = vascular smooth muscle cells, MGP = matrix Gla protein, OPG = osteoprotegerin, ldlr = low-density
lipoprotein receptor, HFD = high-fat diet, MOVAS = mouse vascular smooth muscle cells.
5.2. Vascular Calcification and Osteocalcin in Animal Models
Vascular homeostasis is regulated by a tight balance between pro- and anti-mineralizing osteogenic
factors. Several of these regulatory factors include matrix Gla protein (MGP), osteoprotegerin
(OPG), fetuin A, and inorganic phosphate [79]. MGP and osteocalcin belong to the same family
of mineral-binding Gla proteins, both characterized by vitamin K-dependent post translational
y-carboxylation, and MGP is a known inhibitor of vascular calcification [80]. MGP-deficient mice
are characterized by the development of calcified aortas and early death due to vascular thrombosis
and hemorrhage [74,81]. MGP knockout mice were inter-crossed with pSM22α-Osteocalcin to
create an osteocalcin gain-of-function model. Four-week-old pSM22α-Osteocalcin mice exhibited
no difference in mineralization from the MGP knockout model, despite a 6- to 8-fold increase in serum
osteocalcin concentration [74]. The results from this study demonstrate that total osteocalcin has no
anti-mineralization effect.
Osteoprotegerin (OPG) is a circulating bone marker that functions to inhibit osteoclast activity [82].
OPG-deficient mice are characterized by osteoporosis [83]. Interestingly, OPG-deficient mice are
associated with an increase in vascular calcification, suggesting that OPG may have a protective
role in vascular calcification [75,83]. In a low-density lipoprotein receptor (ldlr) knockout mouse
model treated with OPG and fed a high-fat diet, circulating total osteocalcin was reduced compared
to vehicle-treated mice after two and five months. This was associated with the development of
significantly less calcified lesions, suggesting that lower circulating total osteocalcin is correlated
with a reduction in mouse aortic calcification [76]. Furthermore, cultured thoracic aorta of C57BL/6
mice revealed that increased calcification was positively correlated with an increase in osteocalcin
expression [77]. As such, it appears that total osteocalcin is increased in animal tissue undergoing
calcification, which may result from the differentiation of VSMCs to an osteogenic phenotype. Whether
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this association results in a biological effect, either protective or negative, cannot be determined from
these studies.
A recent study reported that total osteocalcin stimulates glucose metabolism in vascular cells
via hypoxia-inducible factor 1α (HIF-1α), a process that also results in the increase of vascular
calcification [78]. Specifically, osteocalcin overexpression and treatment upregulated insulin signaling
and the expression of glucose transporters through the increase in HIF-1α in mouse vascular smooth
muscle cells (MOVAS). Furthermore, MOVAS cultured in DMEM medium for 21 days developed
mineralized nodules and shifted to an osteogenic phenotype, a process that increases the expression of
osteocalcin [78]. In an in vivo rat model of vascular calcification, total osteocalcin mRNA was positively
associated with the presence of calcification. Immunohistochemistry analysis demonstrated similar
expression patterns between total osteocalcin and the hypoxia-inducible factor 1α (HIF-1α) protein.
Moreover, the silencing of osteocalcin RNA prevented HIF-1α stabilization and inhibited HIF-1α
expression, which resulted in a reduction of calcification and a suppression of osteochondrogenic
differentiation [78]. Altogether, this study demonstrates that total osteocalcin activates HIF-1α
to upregulate glucose transport and utilization. The alteration to glucose metabolism stimulates
osteogenic differentiation and promotes vascular calcification.
To date, there are a limited number of studies that examine the biological effect of osteocalcin
on vascular calcification. A number of different methodologies and models of calcification have been
used, and importantly, no studies distinguished between each form of osteocalcin. Yet, most studies
demonstrate that osteocalcin expression and concentration increase with the degree of calcification.
However, the increase in total osteocalcin expression may be due to the fact that VSMCs differentiate
into an osteogenic phenotype and produce osteocalcin. Further investigation is needed to determine if
osteocalcin is a mediator or a marker of vascular calcification.
6. The Putative Osteocalcin Receptor: GPRC6A
Osteocalcin’s receptor in the vasculature is yet to be identified. The G protein-coupled receptor
family C, group 6, subtype A (GPRC6A) has been suggested as the putative receptor for osteocalcin in
several tissues [84–86]. Previous studies have identified GPRC6A as the osteocalcin receptor in the
testes [87], β-cells [88], and skeletal muscle [89,90] of mice. In humans, GPRC6A has been identified
as the osteocalcin receptor in the testes [91,92]. However, several studies report that ucOC does not
activate this G-protein [93,94].
There is minimal evidence regarding the role of GPRC6A as the receptor for osteocalcin in the
vasculature. GPRC6A is present in the vasculature of rats [95], but whether osteocalcin interacts with
this receptor is presently unknown. Overall, future studies should aim to elucidate whether GPRC6A
is the receptor for osteocalcin in the vasculature, and also examine whether ucOC affects the MAPK
pathway in human vascular cells.
7. Future Directions
The current review highlights that to date, most of the evidence for a link between osteocalcin
and atherosclerosis and blood vessel function focused on total osteocalcin and, to a lesser extent,
its forms (cOC and ucOC). Therefore, future studies should focus on the effect of each form of ucOC
on atherosclerosis, blood vessels, and vascular calcification. Furthermore, it will be important to
identify if there is a direct effect of ucOC on the vasculature or whether the interaction is indirect
via an improvement in glucose regulation and glycemic control. As such, it is important to identify
off-target effects.
8. Summary and Conclusions
The aim of this review was to examine the biological functions of osteocalcin and its forms
throughout the atherosclerosis disease process and to determine whether it functions independently
of metabolic outcomes. It appears that total osteocalcin and ucOC have the potential to improve
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endothelial function and reduce the pathological mechanisms that promote the development of
atherosclerosis. This effect is often a result of improved metabolic outcomes; however, whether there is
a direct osteocalcin/vascular interaction is yet to be fully elucidated. Further, the effect of osteocalcin
on vascular calcification is unclear. In most cases, calcification was associated with the presence of total
osteocalcin, which increased relative to the degree of calcification. However, whether it is a mediator
or a marker of vascular calcification requires further investigation.
In conclusion, there is evidence to suggest that a cross-talk exists between the skeleton and
the vascular system, which is associated with aspects of atherogenesis. Further research is required
to determine whether total osteocalcin or each of its forms has a direct effect on the vasculature,
independent from other systems.
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